Diphtheria Antitoxin Production and Procurement Practices and Challenges.

Area of Science:

• Infectious Diseases
• Immunology
• Public Health Preparedness

Background:

• Respiratory diphtheria treatment necessitates rapid equine diphtheria antitoxin (DAT) administration to neutralize circulating toxins.
• Global outbreaks of diphtheria present ongoing public health challenges.

Purpose of the Study:

• To assess the current market dynamics, including pricing and availability, of equine diphtheria antitoxin (DAT).
• To identify challenges in predicting DAT demand for manufacturers and procurement agencies.
• To explore the progress and financial obstacles faced by monoclonal antibody developers as potential alternatives.

Main Methods:

• Conducted surveys with key procurement agencies and manufacturers involved in DAT production or acquisition.
• Performed key informant interviews with developers of monoclonal antibody therapies.

Main Results:

• Equine diphtheria antitoxin (DAT) prices and availability exhibit significant variability.
• Accurate demand prediction for DAT is challenging for both manufacturers and procurement entities.
• Concerns exist regarding the insufficient supply of DAT to address escalating global diphtheria outbreaks.
• Monoclonal antibody developers reported financial constraints hindering clinical and manufacturing advancements.

Conclusions:

• The current supply chain for equine diphtheria antitoxin (DAT) faces significant challenges in meeting global demands.
• Financial instability presents a barrier for the development and scaling of alternative diphtheria treatments like monoclonal antibodies.
• Improved forecasting and manufacturing strategies are crucial for ensuring adequate DAT availability during outbreaks.